OTC education efforts for Questran would stress physician consultation, BMS says.
This article was originally published in The Tan Sheet
Executive Summary
OTC QUESTRAN AD CAMPAIGN WOULD STRESS PHYSICIAN CONSULTATION as part of a three-step approach to cholesterol lowering, Bristol-Myers Products President Sion Boney reported during a May 13 meeting of FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees to consider the Rx-to-OTC switch of Questran (cholestyramine). "Everything that we [will] say in advertising has a clear message: consult your physician first -- that is the most important step," Boney emphasized.